comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 00:50:11 - browse：354

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： HPV vaccine, cervical cancer study delivers historic results

explore

WSS

Prior authorization reform is both possible and imperative

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

See how much Covid

Dana Farber says 6 studies to be retracted and 31 corrected

At ASCO, AstraZeneca reports strong data for breast cancer drug

Maisha Meds is a PBM, but don't call it that

hotspot

comprehensive

knowledge

At least 13 dead in Texas as scorching temps continue

See how much Covid

Medical records are filled with copy

Microsoft launches AI tool for clinical documentation through Epic

Hollywood unions extend contract negotiations for actors

Woman returns to dialysis after doctors remove transplanted pig kidney

Guidelines to prevent youth baseball injuries need more muscle

FDA endorses new sterilization method for medical devices

As demand for Covid shots wanes, Moderna seeks its next success

Prior authorization reform is both possible and imperative

focus

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

CVS is on a mission to consolidate health care. Will it work?

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO: AstraZeneca says CAR

Mass General, Mayo Clinic look to monetize custom

ASCO: AstraZeneca says CAR

focus

leisure time

explore

knowledge